Precision BioSciences Q1 2024 revenue $17.6M, net income $8.6M; cash runway into H2 2026

PRECISION BIOSCIENCES INC

2024-Q1 EPS reported $1.70 revenue$17,584,000

Revenue $17.6M (up from $8.8M YoY); net income $8.6M vs loss $25.1M in Q1 2023.
Cash and equivalents $137.8M; cash runway extended into H2 2026 via $40M equity offering.
PBGENE-HBV on track for IND/CTA filing in 2024; PBGENE-PMM expected in 2025.
iECURE's OTC gene editing program opened enrollment in UK, first in vivo ARCUS trial.
Regained rights to three preclinical programs (DMD, liver, CNS) from Prevail collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.